Institute of Industrial Property (INPI) of Argentina, from 2010 to 2020 inclusive. The research includes the protected subject …, where the characteristics of the patent applications and granted patents, ownership and nationality of the applicants …, status of the applications, the time it takes to process a patent application and divisional patents are examined. The …

would delay the entry of affordable biologics (biosimilars) into markets. …The test data rule concerning biological medicines (hereafter biologics) has been suspended from the scope of … commendable from the general standpoint of access to medicines and biologics in particular, the suspended provision may not …

a lower price. Argentina is a country that has drug production infrastructure and could potentially become an efficient … exporter. This paper explores the possible implementation of art. 31 bis in Argentina's legislation, proposing to incorporate … into the national patent law the concept of humanitarian compulsory licensing. …

royalties for Argentina through a payment range that takes into consideration criteria of accessibility and affordability of the …

royalties for Argentina through a payment range that takes into consideration criteria of accessibility and affordability of the …

a lower price. Argentina is a country that has drug production infrastructure and could potentially become an efficient … exporter. This paper explores the possible implementation of art. 31 bis in Argentina's legislation, proposing to incorporate … into the national patent law the concept of humanitarian compulsory licensing. …

Agreement) of an exception allowing for the manufacture and export of patent-protected products. It concludes that such an … exception would promote competition and enhance access to medicines (including biologicals) for the general public while being …

Agreement) of an exception allowing for the manufacture and export of patent-protected products. It concludes that such an … exception would promote competition and enhance access to medicines (including biologicals) for the general public while being …